Status:
UNKNOWN
Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
Lead Sponsor:
Hamamatsu University
Collaborating Sponsors:
Yokoyama Foundation for Clinical Pharmacology
Conditions:
Helicobacter Infections
Gastritis
Eligibility:
All Genders
15-90 years
Phase:
PHASE3
Brief Summary
The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor \[PPI\], amoxicillin and clarithromycin) depends on bacterial susceptibility...
Detailed Description
Current treatment strategies for the eradication of H. pylori include a proton pump inhibitor (PPI) and one or two anti-bacterial agents, such as amoxicillin, clarithromycin, and metronidazole. PPIs,...
Eligibility Criteria
Inclusion
- Patients with H. pylori infection
Exclusion
- Patients without H. pylori infection
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT00149084
Start Date
April 1 2003
Last Update
September 11 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan, 431-3192